Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
AssigneeRoche Glycart AG
InventorsPablo Umaña, Ekkehard Mössner
Life of this patent
Estimating the term…
Loading patent…
AssigneeRoche Glycart AG
InventorsPablo Umaña, Ekkehard Mössner
Estimating the term…
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
An isolated polypeptide comprising a sequence selected from the group consisting of:
An isolated polypeptide comprising the sequence of SEQ ID NO:45 having an amino acid substitution selected from the group consisting of:
An antigen binding molecule that specifically binds EGFR, comprising:
An antigen binding molecule that specifically binds EGFR, comprising:
An antigen binding molecule that specifically binds EGFR, comprising:
An antigen binding molecule that specifically binds EGFR, comprising:
An antigen binding molecule that specifically binds EGFR, comprising:
Dependencies are inferred from the claim text.